ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Kidney Transplantation in ESKD Patients with a History of Sickle Cell Disease/Trait

A. Lee, G. Malat, M. Harhay, L. Levin, G. Xiao, S. Guy, D. Reich, K. Ranganna.

Department of Medicine, Division of Nephrology & Hypertension, Drexel University College of Medicine, Philadelphia, PA.

Meeting: 2018 American Transplant Congress

Abstract number: A138

Keywords: African-American, Graft survival, Kidney transplantation, Renal function

Session Information

Date: Saturday, June 2, 2018

Session Name: Poster Session A: Kidney Complications: Late Graft Failure

Session Time: 5:30pm-7:30pm

 Presentation Time: 5:30pm-7:30pm

Location: Hall 4EF

Related Abstracts
  • Safety of Liver Donation from Living Donors with Sickle Cell Trait.
  • Results of Stem Cell and Renal Transplantation in Patients with End Stage Renal Disease After Plasma Cell Dyscrasias.

Introduction:

Kidney transplantation in Sickle Cell Disease patients is fraught with complications, including increased risk of infection and thrombosis. We present long term outcomes of patients with underlying sickle cell disease following successful kidney transplantation.

Methods:

We performed ~700 kidney transplants over the last 10 years. We identified 8 kidney transplant recipients (9 kidney transplants – 1 patient received 2 transplants) who had a history of sickle cell disease or trait. We sought to describe long term patient and allograft outcomes, including: immunosuppression management, perioperative characteristics,incidence of readmissions, complications, patient and graft survival

Results:

All of them were deceased donor recipients. 100% of the patients were African American, and 66% were female. One patient required re-transplantation. Induction was basiliximab in the early period (2007-09), but later changed to anti-thymocyte globulin (33% vs. 66%). Maintenance immunosuppression included calcineurin inhibitor (88% tacrolimus) based immunosuppression in all patients with mycophenolate as adjunctive therapy. 66% of kidney transplants received steroid maintenance immunosuppression, while the remaining 33% of cases were managed with a steroid withdrawal protocol. Length of stay following transplantation in the earlier period was 17-20 days, while our recent cohort had lengths of stay between 7-11 days. Readmissions were common; causes included infection (44%), sickle cell crises (33%), and allograft rejection (22%). Causes of graft failure included death with a functioning graft (1, secondary to fungemia), and rejection (22%). At 6 months post-transplant, 77% of transplants had eGFR > 60 mL/min and 37% had eGFR >60ml/min at 1 year. Patient survival and graft survival at 1 year is 100% and at 3 year is 80% and 60% respectively. 3 recipients who have not reached 3 year mark continue to maintain excellent graft function.

Conclusion:

Kidney transplantation can be successful in recipients with sickle cell disease/trait. Complications are common, including infection and sickle cell crisis. Appropriate immunosuppression is essential, as the group remains at risk for allograft rejection, as well as serious infections. We suggest vigilant care of such patients following kidney transplantation.

CITATION INFORMATION: Lee A., Malat G., Harhay M., Levin L., Xiao G., Guy S., Reich D., Ranganna K. Kidney Transplantation in ESKD Patients with a History of Sickle Cell Disease/Trait Am J Transplant. 2017;17 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Lee A, Malat G, Harhay M, Levin L, Xiao G, Guy S, Reich D, Ranganna K. Kidney Transplantation in ESKD Patients with a History of Sickle Cell Disease/Trait [abstract]. https://atcmeetingabstracts.com/abstract/kidney-transplantation-in-eskd-patients-with-a-history-of-sickle-cell-disease-trait/. Accessed February 27, 2021.

« Back to 2018 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Penis Transplantation: First U.S. Experience.
      • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
      • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
      • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
      • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

      Visit Our Partner Sites

      American Transplant Congress (ATC)

      Visit the official site for the American Transplant Congress »

      American Journal of Transplantation

      The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

      American Society of Transplantation (AST)

      An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

      American Society of Transplant Surgeons (ASTS)

      The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

      Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

      Privacy Policy

      loading Cancel
      Post was not sent - check your email addresses!
      Email check failed, please try again
      Sorry, your blog cannot share posts by email.
      This site uses cookies: Find out more.